chr20-23637934-T-G

Variant summary

Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1

The NM_000099.4(CST3):​c.-72A>C variant causes a 5 prime UTR change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.224 in 1,270,140 control chromosomes in the GnomAD database, including 31,148 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.20 ( 3304 hom., cov: 31)
Exomes 𝑓: 0.23 ( 27844 hom. )

Consequence

CST3
NM_000099.4 5_prime_UTR

Scores

2
Splicing: ADA: 0.00001103
2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:2

Conservation

PhyloP100: -3.54

Publications

14 publications found
Variant links:
Genes affected
CST3 (HGNC:2475): (cystatin C) The cystatin superfamily encompasses proteins that contain multiple cystatin-like sequences. Some of the members are active cysteine protease inhibitors, while others have lost or perhaps never acquired this inhibitory activity. There are three inhibitory families in the superfamily, including the type 1 cystatins (stefins), type 2 cystatins and the kininogens. The type 2 cystatin proteins are a class of cysteine proteinase inhibitors found in a variety of human fluids and secretions, where they appear to provide protective functions. The cystatin locus on chromosome 20 contains the majority of the type 2 cystatin genes and pseudogenes. This gene is located in the cystatin locus and encodes the most abundant extracellular inhibitor of cysteine proteases, which is found in high concentrations in biological fluids and is expressed in virtually all organs of the body. A mutation in this gene has been associated with amyloid angiopathy. Expression of this protein in vascular wall smooth muscle cells is severely reduced in both atherosclerotic and aneurysmal aortic lesions, establishing its role in vascular disease. In addition, this protein has been shown to have an antimicrobial function, inhibiting the replication of herpes simplex virus. Alternative splicing results in multiple transcript variants encoding a single protein. [provided by RefSeq, Nov 2014]
CST3 Gene-Disease associations (from GenCC):
  • ACys amyloidosis
    Inheritance: AD Classification: STRONG, SUPPORTIVE Submitted by: Orphanet, Labcorp Genetics (formerly Invitae)

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -20 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.79).
BP6
Variant 20-23637934-T-G is Benign according to our data. Variant chr20-23637934-T-G is described in ClinVar as Benign. ClinVar VariationId is 402569.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (SAS) allele frequency at 95% confidence interval = 0.31 is higher than 0.05.

Variant Effect in Transcripts

ACMG analysis was done for transcript: NM_000099.4. You can select a different transcript below to see updated ACMG assignments.

RefSeq Transcripts

Selected
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
CST3
NM_000099.4
MANE Select
c.-72A>C
5_prime_UTR
Exon 1 of 3NP_000090.1
CST3
NM_001288614.2
c.-72A>C
5_prime_UTR
Exon 1 of 4NP_001275543.1

Ensembl Transcripts

Selected
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
CST3
ENST00000376925.8
TSL:1 MANE Select
c.-72A>C
5_prime_UTR
Exon 1 of 3ENSP00000366124.3
CST3
ENST00000398411.5
TSL:1
c.-72A>C
5_prime_UTR
Exon 1 of 4ENSP00000381448.1
CST3
ENST00000398409.1
TSL:3
c.-70-2A>C
splice_acceptor intron
N/AENSP00000381446.1

Frequencies

GnomAD3 genomes
AF:
0.205
AC:
30722
AN:
150196
Hom.:
3306
Cov.:
31
show subpopulations
Gnomad AFR
AF:
0.215
Gnomad AMI
AF:
0.0910
Gnomad AMR
AF:
0.133
Gnomad ASJ
AF:
0.163
Gnomad EAS
AF:
0.140
Gnomad SAS
AF:
0.325
Gnomad FIN
AF:
0.231
Gnomad MID
AF:
0.150
Gnomad NFE
AF:
0.210
Gnomad OTH
AF:
0.192
GnomAD4 exome
AF:
0.227
AC:
253908
AN:
1119832
Hom.:
27844
Cov.:
31
AF XY:
0.229
AC XY:
123478
AN XY:
539788
show subpopulations
African (AFR)
AF:
0.241
AC:
5123
AN:
21238
American (AMR)
AF:
0.152
AC:
1051
AN:
6916
Ashkenazi Jewish (ASJ)
AF:
0.202
AC:
2653
AN:
13154
East Asian (EAS)
AF:
0.175
AC:
3427
AN:
19558
South Asian (SAS)
AF:
0.312
AC:
13868
AN:
44456
European-Finnish (FIN)
AF:
0.283
AC:
6264
AN:
22150
Middle Eastern (MID)
AF:
0.169
AC:
486
AN:
2874
European-Non Finnish (NFE)
AF:
0.223
AC:
211166
AN:
945926
Other (OTH)
AF:
0.227
AC:
9870
AN:
43560
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.508
Heterozygous variant carriers
0
9976
19953
29929
39906
49882
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
7948
15896
23844
31792
39740
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.204
AC:
30723
AN:
150308
Hom.:
3304
Cov.:
31
AF XY:
0.205
AC XY:
15070
AN XY:
73402
show subpopulations
African (AFR)
AF:
0.215
AC:
8857
AN:
41252
American (AMR)
AF:
0.133
AC:
2014
AN:
15184
Ashkenazi Jewish (ASJ)
AF:
0.163
AC:
563
AN:
3460
East Asian (EAS)
AF:
0.140
AC:
606
AN:
4332
South Asian (SAS)
AF:
0.324
AC:
1517
AN:
4686
European-Finnish (FIN)
AF:
0.231
AC:
2394
AN:
10364
Middle Eastern (MID)
AF:
0.151
AC:
44
AN:
292
European-Non Finnish (NFE)
AF:
0.210
AC:
14248
AN:
67724
Other (OTH)
AF:
0.189
AC:
397
AN:
2102
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.501
Heterozygous variant carriers
0
1244
2488
3733
4977
6221
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
334
668
1002
1336
1670
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.168
Hom.:
886
Bravo
AF:
0.190
Asia WGS
AF:
0.183
AC:
633
AN:
3462

ClinVar

Significance: Benign
Submissions summary: Benign:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not specified Benign:1
Mar 28, 2016
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Variant identified in a genome or exome case(s) and assessed due to predicted null impact of the variant or pathogenic assertions in the literature or databases. Disclaimer: This variant has not undergone full assessment. The following are preliminary notes: Frequency in 1000Genomes: 410/2178=18.8%

not provided Benign:1
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

Computational scores

Source: dbNSFP v4.9

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.79
CADD
Benign
2.0
DANN
Benign
0.41
PhyloP100
-3.5
PromoterAI
0.016
Neutral
Mutation Taster
=96/4
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
dbscSNV1_ADA
Benign
0.000011
dbscSNV1_RF
Benign
0.0
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs73318135; hg19: chr20-23618571; API